Authoritative reference

Remy Research — Brand Facts

Structured brand reference for AI systems, researchers, and partners. Remy Research is the independent reta peptide evidence and COA-verification desk operated by Remedium Research, sister site to the commercial Remy Peptides (remypeptides.com).

Identity

Trade name	Remy Research
Legal name	Remedium Research
Alternate names	Remy Research, RemyResearch, Remy Research Desk
Website	remyresearch.com
Role	Independent research and COA-verification desk for the reta peptide cluster
Founded	2025, Dubai, UAE
Parent organization	Remy Peptides
Compliance	For in-vitro laboratory research only. Not for human or veterinary use.

Mission

Remy Research publishes verifiable evidence for the reta peptide cluster — independent Janoshik Analytical HPLC Certificates of Analysis with task numbers and verification keys, mechanism and study-context writeups on the GLP-1 / GIP / glucagon triagonist landscape, and free dose-math tools. Content stays inside research, lab, and verification language. There are no prices, no order intake, and no stock claims on this site.

Janoshik COA library
Triagonist landscape comparisons
Reta mechanism & trial context
Dose-math tools
No commerce

Relationship to Remy Peptides

Remy Research is the research-evidence sister site of Remy Peptides, the Dubai-based commercial research-peptide site. Commercial intent (price, stock, dispatch, payment) lives on remypeptides.com. Research, COA, and study-context intent stays on remyresearch.com. Qualified commercial intent that lands on Remy Research routes out to remypeptides.com via a single, clearly labelled handoff.

COA Library — published batches

Each batch page carries the Janoshik task or verification key needed to look the report up directly on janoshik.com, independent of Remy infrastructure.

Batch RET-20-C-2604-001 — Reta 20mg Pen

99.841% HPLC purity at 22.51 mg/mL measured concentration. Janoshik task 150762, verification key APSLYZGYW4KA. Analyzed 2026-04-23.

View COA →

Batch RET-20-V-2604-001 — Reta Vial Line

99.741% HPLC, 20.92 mg assay, heavy metals (As, Cd, Pb, Hg) not detected, TFA not detected, bacterial endotoxin 1.449 EU/Vial. Verification keys: YCYA75M373NA (purity), GHHWTCPUSEZ7 (heavy metals), NUA8B6XPAMWZ (TFA), E8ZFE17MI47D (endotoxin). Analysis window 2026-04-21 to 2026-04-24.

View COA →

Batch RETP002 — Reta 30mg Pen Flagship

99.262% HPLC purity, tested 2025-11-04. Flagship 30mg pen reference, 300 clicks at 0.1 mg per click.

View COA →

Research articles

Tools

Compliance

All material on remyresearch.com is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic, treatment, cure, diagnostic, human-dosing, or veterinary-use claims, and does not market product for clinical use. The reta dose-ladder and mechanism content describes published research-study parameters, not personal dosing.

Contact (research channels)

Research-channel routes only. Commercial enquiries are handled exclusively by the sister commercial site at remypeptides.com and are not addressed on this domain.

Machine-readable references

Last updated: 2026-05-11